Heat Biologics (HTBX) Plans Presentation ofTopline HS-110 + Opdivo Phase 1b Study in NSCLC at Upcoming Conference

November 17, 2016 7:07 AM EST
Get Alerts HTBX Hot Sheet
Trade HTBX Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Heat Biologics, Inc. (Nasdaq: HTBX) announced that it will be reporting topline results from the Phase Ib study evaluating HS-110, in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo), for the treatment of non-small cell lung cancer (NSCLC), in a Mini Oral Session, at the International Society for the Study of Lung Cancer Annual Meeting, in Vienna, Austria, on December 6th. The presenter will be study principal investigator, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine.

Presentation Details:

Title: Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial

Presentation Type/Title: Mini Oral Session (MA09): Immunotherapy Combinations

Date/Time: December 6, 2016, 8:56 AM EST (14:56 CET)

Presentation Number: MA09.06

The abstract can be viewed under “MA09 - Immunotherapy Combinations,” abstract number MA09.06 at: http://library.iaslc.org/virtual-library-search?product_id=6&author=&category=&date=2016-12-06&session_type=Mini+Oral+Session&session=&presentation=&keyword



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Related Entities

S1

Add Your Comment